These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 29368948)

  • 21. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
    Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
    Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
    Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
    Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
    Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Dirksen CD; Kimman ML; Wijsenbeek MS
    Respir Res; 2020 Jul; 21(1):196. PubMed ID: 32703201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia.
    Cox IA; de Graaff B; Corte TJ; Glaspole I; Chambers DC; Moodley Y; Teoh A; Walters EH; Palmer AJ
    Aust Health Rev; 2021 Dec; 45(6):718-727. PubMed ID: 34706811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France.
    Clay E; Cristeau O; Chafaie R; Pinta A; Mazaleyrat B; Cottin V
    J Mark Access Health Policy; 2019; 7(1):1626171. PubMed ID: 31275535
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
    Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
    Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.
    Loveman E; Copley VR; Colquitt JL; Scott DA; Clegg AJ; Jones J; O'Reilly KM; Singh S; Bausewein C; Wells A
    BMC Pharmacol Toxicol; 2014 Nov; 15():63. PubMed ID: 25410822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idiopathic pulmonary fibrosis: the role of the pharmacy benefit manager in providing access to effective, high-value care.
    Morrow TJ
    Am J Manag Care; 2015 Oct; 21(14 Suppl):s294-301. PubMed ID: 26788616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
    Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
    Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
    Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
    Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
    Di Martino E; Provenzani A; Vitulo P; Polidori P
    Ann Pharmacother; 2021 Jun; 55(6):723-731. PubMed ID: 33054319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
    Rodríguez-Portal JA
    Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
    Amati F; Stainer A; Polelli V; Mantero M; Gramegna A; Blasi F; Aliberti S
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175556
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
    Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
    Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Nintedanib in the treatment of fibrosing interstital lung diseases].
    Lewandowska K
    Pol Merkur Lekarski; 2018 Mar; 44(261):139-141. PubMed ID: 29601564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.